West Pharmaceutical Services, Inc. logo WST - West Pharmaceutical Services, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 3
SELL 1
STRONG
SELL 0
| PRICE TARGET: $330.83 DETAILS
HIGH: $400.00
LOW: $295.00
MEDIAN: $317.50
CONSENSUS: $330.83
UPSIDE: 0.85%

Stock News

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More

Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it was a partial victory on Monday, by the close, the huge gains from the morning were cut in half, and the Dow Jones... Here Are Tuesday's Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More

Jun 09, 2026 03:58 AM • 247wallst.com
Top 50 High-Quality Dividend Growth Stocks For June 2026

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

Jun 08, 2026 12:51 AM • seekingalpha.com
West Appoints Michel Lagarde to be President and Chief Executive Officer

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.

Jun 01, 2026 12:30 PM • prnewswire.com
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength.

Apr 30, 2026 02:41 PM • seekingalpha.com

Price Targets